Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre- and postcapillary pulmonary hypertension.

biomarker left heart disease pulmonary circulation vascular remodeling

Journal

Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 28 09 2022
revised: 25 04 2023
accepted: 30 05 2023
medline: 19 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

Pulmonary hypertension is a common sequelae of left heart failure and may present as isolated postcapillary pulmonary hypertension (Ipc-PH) or combined pre- and postcapillary pulmonary hypertension (Cpc-PH). Clinical features associated with progression from Ipc-PH to Cpc-PH have not yet been described. We extracted clinical data from patients who underwent right heart catheterizations (RHC) on two separate occasions. Ipc-PH was defined as mean pulmonary pressure >20 mmHg, pulmonary capillary wedge pressure >15 mmHg, and pulmonary vascular resistance (PVR) < 3 WU. Progression to Cpc-PH required an increase in PVR to ≥3 WU. We performed a retrospective cohort study with repeated assessments comparing subjects that progressed to Cpc-PH to subjects that remained with Ipc-PH. Of 153 patients with Ipc-PH at baseline who underwent a repeat RHC after a median of 0.7 years (IQR 0.2, 2.1), 33% (50/153) had developed Cpc-PH. In univariate analysis comparing the two groups at baseline, body mass index (BMI) and right atrial pressure were lower, while the prevalence of moderate or worse mitral regurgitation (MR) was higher among those who progressed. In age- and sex-adjusted multivariable analysis, only BMI (OR 0.94, 95% CI 0.90-0.99,

Identifiants

pubmed: 37332851
doi: 10.1002/pul2.12249
pii: PUL212249
pmc: PMC10271598
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12249

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL146588
Pays : United States

Informations de copyright

© 2023 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.

Déclaration de conflit d'intérêts

Anna Hemnes serves as a consultant for United Therapeutics, Janssen, GossamerBio, and Merck. She holds stock in Tenax Therapeutics. The remaining authors declare no conflict of interest.

Références

Circ Heart Fail. 2017 Sep;10(9):
pubmed: 28912263
Eur J Heart Fail. 2018 Apr;20(4):725-734
pubmed: 29148140
Sci Rep. 2019 Dec 20;9(1):19572
pubmed: 31862991
Heart Lung Circ. 2022 Apr;31(4):508-519
pubmed: 34756531
Circulation. 2012 Aug 21;126(8):975-90
pubmed: 22908015
J Am Coll Cardiol. 2013 Oct 29;62(18):1660-1670
pubmed: 23916933
Circulation. 2016 Mar 29;133(13):1240-8
pubmed: 26873944
Int J Cardiovasc Imaging. 2019 Aug;35(8):1465-1472
pubmed: 31123846
J Clin Bioinforma. 2014 Sep 20;4:12
pubmed: 25276338
Eur Respir J. 2018 Apr 4;51(4):
pubmed: 29439019
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1234-46
pubmed: 26181215
JACC Heart Fail. 2015 Jan;3(1):9-16
pubmed: 25453535
J Physiol. 2019 Feb;597(4):1157-1173
pubmed: 29799120
Eur J Heart Fail. 2015 Jan;17(1):74-80
pubmed: 25388783
J Cardiovasc Med (Hagerstown). 2017 Apr;18(4):237-243
pubmed: 27841823
Pulm Circ. 2018 Jan-Mar;8(1):2045893217745019
pubmed: 29251543
J Heart Lung Transplant. 2011 Aug;30(8):904-11
pubmed: 21493097
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):25S-32S
pubmed: 15194175
Int J Cardiol. 2019 May 15;283:152-158
pubmed: 30777406
Catheter Cardiovasc Interv. 2021 Sep;98(3):588-594
pubmed: 33559279
Pulm Circ. 2018 Apr-Jun;8(2):2045894018773049
pubmed: 29718770
J Am Coll Cardiol. 2016 Dec 13;68(23):2525-2536
pubmed: 27931609
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
J Card Fail. 2020 Jan;26(1):26-34
pubmed: 31394199
JACC Heart Fail. 2013 Aug;1(4):290-299
pubmed: 24621932
Pulm Circ. 2016 Sep;6(3):313-21
pubmed: 27683608
Clin Transl Sci. 2010 Feb;3(1):42-8
pubmed: 20443953
Chest. 2009 Jul;136(1):31-36
pubmed: 19188551
Int J Cardiol. 2016 Jun 1;212:379-86
pubmed: 27061467
Circulation. 2012 Jan 17;125(2):289-97
pubmed: 22131357
Chest. 2021 Jan;159(1):302-310
pubmed: 32712226
BMC Cardiovasc Disord. 2020 Sep 10;20(1):408
pubmed: 32912157
Circulation. 1992 Feb;85(2):504-9
pubmed: 1735147
Dtsch Med Wochenschr. 2021 Oct;146(21):e88-e94
pubmed: 34670324
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545974
Eur J Heart Fail. 2020 Mar;22(3):489-498
pubmed: 31908127
Ann Transl Med. 2021 Feb;9(4):351
pubmed: 33708978
Chest. 2013 Mar;143(3):758-766
pubmed: 23580984
Clin Pharmacol Ther. 2008 Sep;84(3):362-9
pubmed: 18500243
Pulm Med. 2018 Mar 01;2018:7056360
pubmed: 29686899
J Heart Lung Transplant. 2012 Sep;31(9):913-33
pubmed: 22884380
J Am Heart Assoc. 2019 Nov 5;8(21):e012086
pubmed: 31657265
Int J Cardiol. 2019 Oct 1;292:205-210
pubmed: 31176524
Pulm Circ. 2021 Mar 2;11(1):2045894021996571
pubmed: 33738094

Auteurs

Gautam Babu (G)

Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA.

Jeffrey S Annis (JS)

Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA.

Jonah D Garry (JD)

Department of Medicine, Division of Cardiovascular Medicine Vanderbilt University Medical Center Nashville Tennessee USA.

Matthew S Freiberg (MS)

Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA.

Anna R Hemnes (AR)

Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA.

Evan L Brittain (EL)

Department of Medicine, Division of Cardiovascular Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Division of Cardiovascular Medicine, Vanderbilt Translational and Clinical Research Center Vanderbilt University Medical Center Nashville Tennessee USA.

Classifications MeSH